New Weight Loss Drug Retatrutide Delivers Double the Results
A new experimental drug called retatrutide has shown greater weight loss than Ozempic in a major diabetes study. Its maker, Eli Lilly, says the drug also improved blood sugar control more than Ozempic.
The results could make retatrutide an important future treatment for people with type 2 diabetes and obesity. However, the drug is still being tested and is not approved for public use.
According to Reuters, the results came from a late-stage trial involving adults with type 2 diabetes. Researchers compared two doses of retatrutide with Ozempic's highest approved dose for diabetes.
How Much Weight Did People Lose with Retatrutide?
The 80-week trial found that people taking the highest dose of retatrutide lost an average of 20.9% of their body weight. Those taking Ozempic lost an average of 9.4%.
The lower dose of retatrutide produced an average weight loss of 19.5%.
For example, imagine a person weighing 100 kilograms at the start of treatment. A weight loss of about 21% would equal roughly 21 kilograms. A 9.4% loss would be about 9 kilograms.
These figures are averages from the study, not promises about what each person will lose.
The study also found that retatrutide improved blood sugar levels. Researchers measured this using A1C, a test that shows average blood sugar over roughly three months.
Retatrutide doses lowered A1C by an average of 2.2 percentage points. Ozempic lowered it by 1.8 percentage points.
Lilly announced the findings on October 28, 2026. The company plans to present detailed results at a future medical meeting.
How Does Retatrutide Work?
Retatrutide works by activating three hormone receptors involved in appetite, blood sugar control, and energy use.
These receptors are linked to three hormones: GLP-1, GIP, and glucagon.
The drug is designed to help people feel less hungry, manage blood sugar, and increase the body's energy expenditure. Researchers hope this combination can produce greater weight loss than medicines that act on fewer hormone pathways.
Retatrutide is given as a once-weekly injection in clinical trials.
However, researchers still need more information about its long-term benefits and risks. A drug that produces greater weight loss may not be the best choice for every patient.
Retatrutide vs Ozempic: What Is the Difference?
Ozempic contains semaglutide and is approved in several countries for the treatment of type 2 diabetes. Its approved uses and doses vary by country.
Retatrutide is an experimental medicine that acts on three hormone receptors. Ozempic acts on the GLP-1 receptor.
The latest trial compared retatrutide doses of 9 milligrams and 12 milligrams with Ozempic 2 milligrams.
Retatrutide produced greater average weight loss and a larger reduction in A1C during the study. It also improved some heart-related risk factors, including blood pressure and certain blood fats.
However, Ozempic has evidence supporting benefits beyond blood sugar and weight. Depending on the patient and product label, semaglutide treatments may also have specific heart or kidney benefits.
Therefore, the results do not mean Ozempic has no value. Treatment decisions depend on a person's health, medical history, and treatment goals.
What Are the Possible Side Effects?
Retatrutide caused side effects in the trial, particularly digestive problems.
Common problems included:
- Diarrhea
- Nausea
- Vomiting
- Constipation
- Indigestion
Some participants stopped treatment because of side effects. This occurred more often with the higher retatrutide dose than with Ozempic in this trial.
For example, someone who experiences repeated vomiting may struggle to drink enough fluids. This can lead to dehydration and may require medical attention.
The full safety picture will become clearer as researchers publish detailed results and follow participants for longer.
When Could Retatrutide Become Available?
The Food and Drug Administration or other regulatory authorities have not approved Retatrutide. Lilly plans to seek US approval in 2027, according to its announcement.
The company is also studying retatrutide in other trials, including a comparison with tirzepatide, the active ingredient in Zepbound and Mounjaro.
Regulators must review the evidence on safety and effectiveness before deciding whether to approve the drug.
People should avoid buying products advertised online as retatrutide. Unapproved products may contain unknown ingredients, incorrect doses, or pose contamination risks.
Anyone considering weight-loss medication should speak with a qualified healthcare professional.
The Bottom Line
Retatrutide has produced promising results in a late-stage trial involving adults with type 2 diabetes. Participants taking the highest dose lost more than twice as much weight on average as those taking Ozempic 2 milligrams.
However, the manufacturer announced the findings, and detailed results are still pending. Retatrutide remains experimental, and its long-term safety and benefits need further review.
Frequently Asked Questions
Is retatrutide better than Ozempic?
In this specific trial involving adults with type 2 diabetes, retatrutide produced greater average weight loss and a larger A1C reduction. More evidence is needed to understand its long-term safety and benefits.
Is retatrutide approved for weight loss?
No. Retatrutide remains an investigational drug and is not approved for public use.
Does retatrutide work for everyone?
No medicine works the same way for everyone. Future studies will help explain which patients may benefit most, and which risks require greater attention.
